• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].

作者信息

Frydman A, Levenson J, Simon A, Safar M, Bieder A, Bertharion J, Gaillot J

出版信息

Nouv Presse Med. 1982 Jun 10;11(27):2049-56.

PMID:7110964
Abstract

The pharmacokinetics of intravenous isosorbide dinitrate was investigated in 11 patients with labile hypertension and with normal renal and hepatic functions. The mode of administration (constant rate infusion without loading dose) was chosen in order to minimize side-effects and to approximate clinical conditions. Isosorbide dinitrate levels were measured by electron-capture gas chromatography. The volume of distribution during steady state (Vd beta = 318 +/- 117 I) and the elimination half-life (t1/2 beta = 64.8 +/- 30.5 min) were similar to those found after perlingual and oral administration. Systemic clearance (Cls = 3.80 +/- 1.48 I/min) was high for a drug given intravenously, presumably because of active hepatic extraction, intensive pre-systemic degradation and very active extra-hepatic metabolism. These findings should be compared with the considerable inter-individual variations observed in theoretical plasma concentrations during steady state and with the presence of two pharmacokinetic models (one -- and two -- compartments) in the patients under study. Comparison of the results obtained by the intravenous route with previously published results after perlingual and oral administration indicates the following bioavailability ratios: perlingual/i.v. = 31%, oral/i.v. = 20%, and oral/perlingual = 63%.

摘要

相似文献

1
[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].
Nouv Presse Med. 1982 Jun 10;11(27):2049-56.
2
Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.硝酸异山梨酯经皮喷雾剂的生物利用度和代谢
Arzneimittelforschung. 1992 Jul;42(7):931-5.
3
Effects of disease, route of administration, cigarette smoking, food intake on the pharmacokinetics and circulatory effects of isosorbide dinitrate.疾病、给药途径、吸烟、食物摄入对硝酸异山梨酯药代动力学及循环系统效应的影响。
Z Kardiol. 1983;72 Suppl 3:5-10.
4
Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.人体静脉输注硝酸异山梨酯后的药代动力学
Biopharm Drug Dispos. 1980 Jan-Mar;1(3):149-56. doi: 10.1002/bdd.2510010310.
5
Fate of orally given isosorbide dinitrate in cirrhotic patients.肝硬化患者口服硝酸异山梨酯的转归
Int J Clin Pharmacol Ther Toxicol. 1984 Sep;22(9):491-2.
6
A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.地尔硫䓬与硝酸异山梨酯对慢性缺血性心力衰竭患者地高辛药效学和药代动力学影响的比较
Saudi Med J. 2002 Jun;23(6):725-31.
7
[Effects of intravenous infusion of isosorbide dinitrate on hemodynamics during anesthesia and surgery].
Masui. 1993 Jan;42(1):71-6.
8
Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.静脉注射和口服后异山梨醇二硝酸酯的药代动力学及代谢
Eur J Clin Pharmacol. 1985;27(6):637-44. doi: 10.1007/BF00547041.
9
Blood and tissue levels of [14C]isosorbide dinitrate after oral and intravenous administration to rat.大鼠口服和静脉注射[14C]硝酸异山梨酯后的血液和组织水平。
J Pharmacol Exp Ther. 1977 Jul;202(1):32-7.
10
Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.静脉输注后硝酸异山梨酯及其单硝酸代谢产物的药代动力学
J Pharmacokinet Biopharm. 1986 Feb;14(1):1-17. doi: 10.1007/BF01059280.

引用本文的文献

1
Clinical pharmacokinetics of organic nitrates.有机硝酸盐的临床药代动力学
Clin Pharmacokinet. 1983 Sep-Oct;8(5):410-21. doi: 10.2165/00003088-198308050-00003.
2
Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.静脉注射和口服后异山梨醇二硝酸酯的药代动力学及代谢
Eur J Clin Pharmacol. 1985;27(6):637-44. doi: 10.1007/BF00547041.
3
Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.静脉输注后硝酸异山梨酯及其单硝酸代谢产物的药代动力学
J Pharmacokinet Biopharm. 1986 Feb;14(1):1-17. doi: 10.1007/BF01059280.
4
Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.
Eur J Clin Pharmacol. 1990;38(2):145-7. doi: 10.1007/BF00265973.